Bibliography
- DE CLERCQ E: The role of non-nucleoside reverse transcriptase inhibitors in the therapy of HIV-1. Antiviral Res. (1998) 38:153–179.
- ••Comprehensive review of recent NNRTIs and theirprominent position in the triple-drug treatment of HIV-1 infection.
- KOHLSTAEDT LA, WANG J, FRIEDMAN JM et al.: Crystal- structure at 3.5 A resolution of HIV-1 reverse-transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
- ••Frequently cited pioneering publication on the bindingmode of an NNRTI (nevirapine) to HIV-1 RT, revealing a binding pocket near but not overlapping with the polymerase active site.
- REN JS, ESNOUF R, GARMAN E et al.: High-resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. (1995) 2:293–302.
- ••High-resolution HIV-1 RT structures revealing a commonmode of binding for these chemically diverse compounds.
- ESNOUF R, REN JS, ROSS C et al.: Mechanism of inhibi- tion of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Nature Struct. Biol. (1995) 2:303–308.
- ••Comparison of the structure of unliganded HIV-1 RT withthe structures of four different RT-NNRTI complexes, suggesting that NNRTIs inhibit RT by locking the polymerase active site in an inactive conformation.
- MIYASAKA T, TANAKA H, BABA M, et al.: A novel lead for specific anti-HIV-1 agents: 1- [(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine. J. Med. Chem. (1989) 32:2507–2509.
- •First report on this novel 6-substituted 'acycyclic' pyrimidine derivative, manifesting its anti-HIV-1 acitivity through an, at the time, unknown mechanism.
- NORBECK DW, SPANTON S, BRODER S: (-4-Dioxolane-T ((±) -1- [(26, 4)-2- (hydroxymethy1-4-dioxolanyfi thymine]. A new 2',3'-dideoxynucleoside prototype with in vitro activity against HIV. Tetrahedron Lett. (1989) 30:6263–6266.
- •First report on the anti-HIV activity of a 3'-heteroatomsubst-ituted nucleoside.
- DU J, SURZHYKOV S, UN JS: Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. J. Med. Chem. (1997) 40.2991–2993.
- •First method for the synthesis of a novel class of a novel class of 3'-heteroatom-substituted nucleosides, i.e. oxaselenolane nucleosides.
- KIM HO, SCHINAZI RF, SHANMUGANATHAN K et al: L-p-(ZS,4s)- and t-a-(25,41H-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J. Merl. Chem. (1993) 36:519–528.
- •Comprehensive structure-activity relationships on the anti-HIV activity of various L-(2S)-dioxolanyl pyrimidines and purines.
- CHU CK, MA TW, SHANMUGANATHAN K et al.: Use of 2'-fluoro-5-methyl-p-t-arabinofuranosyl uracil as novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39:979–981.
- •Discovery of the anti-HBV and anti-EBV agent, L-FMAU.
- WATANABE KA, REICHMAN U, HIROTA K et al: Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J. Med. Chem. (1979) 22:21–24.
- MANSURI MM, FARINA V, STARRETT JE eta].: Preparation of the geometric isomers of DDC, DDA, D4C and D4T as potential anti-HIV agents. Bioorg. Merl. Chem. Lett. (1991) 1:65–68.
- •First paper to pay attention to the antiviral activity of L-enant-iomers of known anti-HIV agents.
- LIN JS, KIRA T, GULLEN E et al.: Structure-activity relationships of t-dioxolane uracil nucleosides as anti-Epstein Barr Virus Agents. J. Med. Chem. (1999) 42:2212–2217.
- SAENGER W: Principles of Nucleic Acid Structure, Springer-Verlag, New York (1984):51–104.
- ••Still considered to be the reference work on conformationalanalysis of nucleotides.